ABSTRACT
As a second-generation AR antagonist, enzalutamide has shown good effects in the treatment of castration-resistant prostate cancer, and has also been used in the treatment of hormone-sensitive prostate cancer. In 2018, a patient with prostate cancer was admitted to Hangzhou First People's Hospital. After radical prostatectomy, the patients was in PSA persistence. After 29 months of endocrine therapy, the patient developed drug resistance against bicalutamide, and PSA increased month by month. PSA dropped back to undetectable after changing bicalutamide to enzalutamine.
ABSTRACT
Objective:To explore the clinical therapeutic effect and the mechanism of Ruanjian Yiqi Huoxue Recipe for treatment of ischemic apoplexy.Methods:80 cases were randomly divided into a treatment group and a control group.Scores of neurologic deficit,clinical therapeutic effects,quality of life,level of tissue plasminogen activator(t-PA)and plasminogen activator inhibitor-1(PAI-1)in the peripheral blood,improvement of abnormal blood lipids and blood pressure were observed before and after treatment.Results: Total effective rate in the treatment group was 85% and 65% in the control group.The score of neurologic deficit and quality of life in the treatment group improved significantly(P
